Bortezomib Use for a Critically Ill Patient with Angioimmunoblastic T-Cell Lymphoma

Angioimmunoblastic T-cell lymphoma (AITL) accounts for 18.5% of all peripheral T-cell lymphomas. There is still no gold standard chemotherapy for treating newly diagnosed AITL. This case describes the use of bortezomib in newly diagnosed AITL. A 53-year-old man with no previous illness presented wit...

Descripción completa

Detalles Bibliográficos
Autor principal: Shibusawa, Motoharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453013/
https://www.ncbi.nlm.nih.gov/pubmed/36092150
http://dx.doi.org/10.1155/2022/6079633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453013/
https://www.ncbi.nlm.nih.gov/pubmed/36092150
http://dx.doi.org/10.1155/2022/6079633

Ejemplares similares